Ceplene 24-month Phase III data

Maxim (MAXM; SSE:MAXM) said 24-month follow-up data from a previously reported U.S. Phase III trial showed advanced melanoma patients treated with Ceplene histamine dihydrochloride (formerly Maxamine) plus interleukin-2 (IL-2) had a statistically significant improvement in survival compared to patients given IL-2 alone (p=0.046). In addition, the company said the 305-patient, open-label trial showed Ceplene and IL-2 significantly increased survival in advanced metastatic melanoma patients with liver metastases (p=0.0028). Data were presented at the European Cancer Conference in Lisbon. ...